Biography for Eric Palmer
Eric Palmer is a business and technology journalist with more than three decades of prize-winning experience as a reporter and editor with daily, weekly, monthly and online publications. He was healthcare reporter for The Kansas City Star before becoming deputy business editor for the daily newspaper. He spent eight years as editor of The Kansas City Business Journal, which had a strong emphasis on the healthcare industry. On the personal side, he is an avid fly fisherman, cooks and collects wine, and likes to travel with his family.
Articles by Eric Palmer
The FDA placed an import ban on products from Ranbaxy Laboratories' active pharmaceutical plant in Toansa, India, in January, calling into question its drug analysis and sanitation. But there are other problems at the plant, like worker safety, that the FDA does not address and which get little attention from Indian authorities.
GlaxoSmithKline, which is making big investments in manufacturing in the U.K., will help its homeland try to figure out how to revive its manufacturing base.
Eli Lilly and Chinese partner Novast have started on a new plant in China to manufacture generic versions of Lilly drugs, a bit of good news on a day when manufacturing issues had otherwise cast a shadow over the Indianapolis-based drugmaker.
Baxter International, which has had ongoing contamination issues with some of its intravenous products, is now recalling one lot of a peritoneal product used on dialysis patients. It says the lot is contaminated with mold. The announcement, also sent out by the FDA, says there have been adverse reactions reported.
Sterile injectables maker Sagent Pharmaceuticals is recalling a product because of leaking bags. It is the second recall in about 9 months for the company, which relies mostly on contractors to manufacture its products.
The FDA has held off approval of a new Eli Lilly diabetes drug until partner Boehringer Ingelheim fixes problems at a plant that last year was slapped with a warning letter.
Regeneron is starting work on a new manufacturing plant in Limerick, Ireland, that it expects to manufacture drugs that are currently in its pipeline. But already the drugmaker is talking about an expansion and building a fill-and-finish plant nearby, at least according to Ireland's minister of finance.
The global drug market is growing and by extension, so is demand for pharma packaging products.
Serving emerging markets generally requires local production--and that means investments in upgrades. That is the phase Eli Lilly is in with a packaging operation in São Paulo, Brazil.
Hospitals say the FDA and drugmakers should loop in hospitals and group purchasing organizations to attack drug shortages the way police would attack a hostage situation.